Filing Details
- Accession Number:
- 0001179110-17-009853
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-06-30 18:20:25
- Reporting Period:
- 2017-06-28
- Filing Date:
- 2017-06-30
- Accepted Time:
- 2017-06-30 18:20:25
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1597264 | Blueprint Medicines Corp | BPMC | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1638468 | L. Anthony Boral | C/O Blueprint Medicines Corporation 38 Sidney Street, Suite 200 Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-06-28 | 10,000 | $8.80 | 10,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-06-28 | 4,586 | $51.08 | 5,414 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-06-28 | 4,314 | $50.19 | 1,100 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-06-28 | 1,100 | $49.07 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2017-06-28 | 10,000 | $0.00 | 10,000 | $8.80 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
179,544 | 2025-02-10 | No | 4 | M | Direct |
Footnotes
- The exercise reported on this Form 4 was effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Exchange Act.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.49 to $51.48 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.59 to $50.48 per share.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.96 to $49.16 per share.
- This option was granted on February 10, 2015. This option vested with respect to 25% of the shares underlying the option on February 9, 2016 and as to an additional 1/48th of the shares underlying the option each month thereafter.